Imagine trying to kill weeds in a garden without harming the flowers; that is how this project treats childhood leukemia. Instead of using harsh chemicals that damage everything, they use smart 'guided missiles' like antibodies and modified immune cells to target only the cancer. It is like upgrading from a sledgehammer to a precision laser to save children's lives with fewer side effects.
Childhood relapsed leukemia has high mortality rates because current chemotherapy is too toxic. There is a critical need for targeted, less toxic therapies that can be validated through large-scale, multi-national clinical trials.
A federated relapsed/refractory leukaemia board and the MARVIN database for trial monitoring and personalized treatment recommendations.
If you are a biotech company dealing with the high cost of orphan drug clinical trials — this project developed a 20-country consortium that provides the infrastructure for large-scale studies. This allows for faster validation of immunotherapy drugs like CD22 directed antibodies.
If you are a software provider dealing with fragmented patient data in multi-center trials — this project developed the MARVIN database to monitor individualized treatments. This proves the need for federated data systems across 20 different countries.
If you are a cell therapy firm dealing with the challenge of scaling academic CAR T-cell production — this project is testing CD19-directed CAR T-cells produced in academic institutions. This provides a blueprint for transitioning academic prototypes to clinical standards.
Based on available project data, the specific costs or pricing for the therapies are not disclosed.
The project involves 26 partners across 20 countries and collaborates with pharmaceutical companies, suggesting a high capacity for scaling clinical trial results to industrial production.
Based on available project data, specific IP or licensing agreements are not mentioned, though the project involves industry partners and regulatory bodies like the EMA.
The consortium collaborates directly with the EMA to ensure trials follow the law and to potentially extend the approval of new drugs.
The project period runs from 2023-05-01 to 2028-04-30.
The consortium is heavily weighted toward clinical and academic research, with 7 universities and 10 research institutes. However, the inclusion of 1 industry partner and 2 SMEs, combined with a massive 20-country reach, indicates a strong bridge between laboratory discovery and market application. The presence of the EMA as a collaborator suggests a strategic focus on regulatory approval and market entry.
Contact Charité - Universitätsmedizin Berlin
Contact us to identify partnership opportunities with the IntReALL 2020 consortium.
